Folia Medica Indonesiana
ISSN 0303-7932
Vol. 51 / No. 1 / Published : 2015-01
Order : 7, and page :35 - 39
Related with : Scholar Yahoo! Bing
Original Article :
Gastrointestinal tolerability of diclofenac sodium and meloxicam in osteoarthritis patient
Author :
- Hendera*1
- Bagus PP Suryana*2
- Yulistiani*3
- Mahasiswa Fakultas Farmasi
- Division of Rheumatology and Immunology, Internal Department, Dr. Saiful Anwar Hospital, Brawijaya University
- Dosen Fakultas Farmasi
Abstract :
NSAIDs are a group of analgesic and antiinflammatory drugs that the most widely used and prescribed around the world. NSAIDs,particularly non-selective NSAIDs (ex. diclofenac sodium), can cause an increased risk of serious, even fatal, stomach and intestinaladverse reactions such as bleeding, ulcers, and perforation of the stomach or intestines. These events can occur at any time duringtreatment and without warning symptoms. Elderly patients are at greater risk for these types of reaction. The aim of this study toevaluate gastrointestinal tolerability of diclofenac sodium twice daily dose of 50 mg compared to meloxicam once daily dose of 15mg on an outpatients with knee OA. The method of this study was cohort prospective observation on August to November 2014.SODA (severity of dyspepsia assessment) scale through interview using a questionnaire was applied to evaluate adverse effect ofabdominal pain and others associated gastrointestinal disturbances at before and after 14 and 28 days of treatment. The resultsshowed that gastrointestinal tolerability of diclofenac sodium was greater compared to meloxicam by abdominal pain scale at day14, that was in the diclofenac sodium group with mean score of 5.47 compared to meloxicam group of 3.12 (p < 0.05) and adverseeffect on upper abdominal pain in the diclofenac sodium group at day 28 increased by mean score of 10.88, while that of meloxicamgroup of 4.94 (p < 0.05). Moreover, the non abdominal pain (i.e belching, heartburn, bloating, passing gas, nausea, and bad breath)in both groups showed no significant difference (p > 0.05). The most common non abdominal pain after 14 and 28 days of treatmentin both groups was upper abdominal bloating. In conclusion, Gastrointestinal tolerability of meloxicam was better than diclofenacsodium based on the side effect of abdominal pain. (FMI 2015;51:35-39)
Keyword :
diclofenac sodium, gastrointestinal tolerability, meloxicam, nonsteroidal antiinflammatory drugs, NSAIDs,
References :
López-Pintor E and Lumbreras B ,(2011) Use of gastrointestinal prophylaxis in NSAID patients: a cross sectional study in community pharmacies 33, 155-164 : Int J Clin Pharm
Park EJ and Kwon TK ,(2011) Rottlerin enhances IL- 1β-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cells 43, 669-675 : Experimental & Molecular Medicine
Archive Article
Cover Media | Content |
---|---|
![]() Volume : 51 / No. : 1 / Pub. : 2015-01 |
|